프로티나

468530KOSDAQ자연과학 및 공학 연구개발업

53.8 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40

News Sentiment18.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 31.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ProtiNA is a PPI big data company specializing in high-speed, large-scale analysis of protein-protein interactions (PPI) using its proprietary SPID platform. The SPID technology offers up to 100 times higher sensitivity than traditional methods and is applied in drug development, biomarker discovery, and antibody design. The company provides solutions like PPI PathFinder® and PPI Landscape® for pharmaceutical research.

Number of Employees

53people

Average Salary

70.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-40.84Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

5.62Industry Average 7.525.0Point

Lower than industry avg (good)

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 75

Neutral
가속도 붙은 中 신약개발…"K바이오 전략 수정 필요"
중국의 신약 개발이 가속화되면서 한국 바이오산업은 중국과의 협력에 초점을 맞추는 전략이 유리할 수 있다는 분석이 나왔습니다.
Positive
KBIOHealth-프로티나, AI 기반 신약 개발 역량 강화 업무 협...
오송첨단의료산업진흥재단(KBIOHealth)이 신약 개발 기업 프로티나와 AI 기반 신약 개발 역량 강화를 위한 업무협약(MOU)을 체결했습니다.
Positive
제약바이오 정책간담회서 기업들이 금융위만 찾은 이유[현장+]
중소벤처기업부와 보건복지부가 제약바이오벤처 혁신성장 전주기 협업방안 발표회를 개최하며 금융위원회의 참여를 요청하는 목소리가 나왔습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 58,200Won52-week high 111,80052-week low 13,800

1-month return0.0Point

1m -31.53% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-30
Neutral사업보고서 (2025.12)2026-03-20
Neutral감사보고서제출2026-03-20